Company: INDP
Filing Date: 2025-03-27
Form Type: DRS
Source: 0001641172-25-000975
Chunk: 24

Company: Indaptus Therapeutics, Inc.
Filing Date: 2025-03-27
Form: DRS
Chunk 24
---
 stock and warrants to purchase 2,109,383 shares of common stock at a combined purchase price of $1.065 per share and accompanying warrant for aggregate gross proceeds of $2,246,500; (ii) the issuance and sale by us of 1,400,000 shares of common stock as Advance Shares under the SEPA for aggregate gross proceeds of approximately $1.1 million; and (iii) the issuance by us of 305,960 shares of common stock as Commitment Shares under the SEPA, our pro forma net tangible book value as of December 31, 2024, would have been approximately $7.0 million, or approximately $0.440 per share.

After giving further effect to the assumed sale by us of all shares of common stock and accompanying common warrants offered by means of this prospectus at an assumed combined public offering price of $ per share and accompanying common warrant, which is based on the last reported sale price of our shares of common stock on Nasdaq on , 2025, assuming no sale of pre-funded warrants and after deducting the Placement Agent’s fees and estimated offering expenses payable by us, and without giving effect to the exercise of the common warrants issued in this offering, our pro forma as adjusted net tangible book value as of December 31, 2024 would have been approximately $ million, or approximately $ per share. This represents an immediate increase in net tangible book value of approximately $ per share to existing stockholders and an immediate dilution of approximately $ per share to new investors in this offering. The following table illustrates this per share dilution:

| Assumed combined public offering price per share and accompanying common warrant                         
 Net tangible book value per share as of December 31, 2024                                                
 Pro forma net tangible book value per share as of December 31, 2024 after giving effect to the Pro Forma 
 Adjustments                                                                                              |     |   | 0.329 
 0.440 |
|:---------------------------------------------------------------------------------------------------------|:----|:--|:------|
| Increase per share attributable to new investors in this offering                                        |     | $ |       |
| Pro forma as adjusted net tangible book value per share as of December 31, 2024 after giving effect      
 to this offering                                                                                         |     | $ |       |
| Dilution in net tangible book value per share to new investors in this offering                          |     | $ |       |

Each $0.10 increase (decrease) in an assumed combined public offering price